Leerink Partnrs Analysts Increase Earnings Estimates for Edwards Lifesciences Co. (NYSE:EW)

Edwards Lifesciences Co. (NYSE:EW) – Stock analysts at Leerink Partnrs raised their Q2 2024 EPS estimates for Edwards Lifesciences in a research note issued on Thursday, March 28th. Leerink Partnrs analyst M. Kratky now forecasts that the medical research company will earn $0.72 per share for the quarter, up from their prior forecast of $0.71. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.76 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences’ FY2024 earnings at $2.78 EPS, Q1 2025 earnings at $0.75 EPS, Q2 2025 earnings at $0.80 EPS, Q3 2025 earnings at $0.81 EPS, Q4 2025 earnings at $0.82 EPS, FY2025 earnings at $3.19 EPS, FY2026 earnings at $3.61 EPS, FY2027 earnings at $4.04 EPS and FY2028 earnings at $4.38 EPS.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.64. The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. During the same period in the prior year, the business earned $0.64 EPS. The firm’s quarterly revenue was up 13.3% on a year-over-year basis.

Other analysts have also issued reports about the stock. StockNews.com lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, March 20th. Wells Fargo & Company upgraded shares of Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 price objective on the stock in a report on Friday, February 2nd. Morgan Stanley increased their target price on Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a report on Thursday, March 21st. Royal Bank of Canada upped their price objective on Edwards Lifesciences from $82.00 to $95.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. Finally, Citigroup downgraded Edwards Lifesciences from a “buy” rating to a “neutral” rating in a report on Monday, December 11th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $88.80.

Edwards Lifesciences Trading Up 0.4 %

EW opened at $95.53 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.38 and a quick ratio of 2.40. The stock has a market capitalization of $57.50 billion, a price-to-earnings ratio of 41.53, a PEG ratio of 4.72 and a beta of 1.05. The business has a fifty day moving average price of $85.90 and a 200 day moving average price of $75.99. Edwards Lifesciences has a 12 month low of $60.57 and a 12 month high of $96.12.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Catherine M. Szyman sold 27,000 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the completion of the sale, the vice president now directly owns 34,814 shares of the company’s stock, valued at approximately $2,980,774.68. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, VP Catherine M. Szyman sold 27,000 shares of the business’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the transaction, the vice president now directly owns 34,814 shares in the company, valued at $2,980,774.68. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 10,000 shares of the firm’s stock in a transaction dated Friday, January 12th. The shares were sold at an average price of $75.67, for a total transaction of $756,700.00. Following the completion of the sale, the vice president now owns 39,503 shares of the company’s stock, valued at approximately $2,989,192.01. The disclosure for this sale can be found here. Insiders sold a total of 182,349 shares of company stock worth $15,334,555 in the last 90 days. Company insiders own 1.29% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Several institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in shares of Edwards Lifesciences by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 52,363,400 shares of the medical research company’s stock valued at $3,992,709,000 after purchasing an additional 729,984 shares during the period. State Street Corp boosted its stake in shares of Edwards Lifesciences by 0.4% during the 2nd quarter. State Street Corp now owns 27,053,304 shares of the medical research company’s stock worth $2,551,938,000 after acquiring an additional 108,102 shares in the last quarter. Alliancebernstein L.P. grew its holdings in shares of Edwards Lifesciences by 0.3% in the 2nd quarter. Alliancebernstein L.P. now owns 20,512,235 shares of the medical research company’s stock worth $1,934,919,000 after acquiring an additional 66,763 shares during the period. Brown Advisory Inc. increased its stake in Edwards Lifesciences by 20.1% in the 4th quarter. Brown Advisory Inc. now owns 18,181,420 shares of the medical research company’s stock valued at $1,386,333,000 after purchasing an additional 3,048,274 shares in the last quarter. Finally, Wellington Management Group LLP raised its holdings in Edwards Lifesciences by 2.4% during the fourth quarter. Wellington Management Group LLP now owns 16,827,510 shares of the medical research company’s stock worth $1,283,098,000 after purchasing an additional 393,109 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.